125I seed brachytherapy synergized with PD-1 inhibitor imparts potent antitumor immune responses in hepatocellular carcinoma
Our brachy-primed immunotherapy approach offers a promising and effective treatment strategy, which may improve the immunotherapeutic efficacy in HCC.
Authors
- Jin‐He Guo (ORCID: https://orcid.org/0000-0002-4620-2930)
- Duo Shen (ORCID: https://orcid.org/0000-0002-2715-1090)
- Hai‐Dong Zhu (ORCID: https://orcid.org/0000-0003-1798-7641)
- Peng Zeng (ORCID: https://orcid.org/0000-0003-1606-7528)
- Rong Chen (ORCID: https://orcid.org/0000-0002-6716-0071)
- Yong Wang (ORCID: https://orcid.org/0000-0002-0123-228X)
- Gao‐Jun Teng (ORCID: https://orcid.org/0000-0002-5951-4538)
- Tiancheng Zhao (ORCID: https://orcid.org/0009-0009-5034-4163)
Institutions
- University of California, Los Angeles (US)
- Zhongda Hospital Southeast University (CN)
- Changzhou No.2 People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.ctro.2025.101083
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Southeast University
- National Key Research and Development Program of China